Bacterial derived nanovesicles for drug delivery and vaccine applications
Antimicrobial resistance is one of the most urgent global challenges we face today. Traditional efforts of discovering and synthesising new antibiotics is facing a bottleneck, and cannot keep up with the rate at which bacteria newly acquires resistance genes. It is hence imperative to rely on...
Saved in:
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Final Year Project |
| Language: | English |
| Published: |
Nanyang Technological University
2023
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10356/166584 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Nanyang Technological University |
| Language: | English |
| Summary: | Antimicrobial resistance is one of the most urgent global challenges we face today.
Traditional efforts of discovering and synthesising new antibiotics is facing a
bottleneck, and cannot keep up with the rate at which bacteria newly acquires
resistance genes. It is hence imperative to rely on alternative solutions such as the use
of better drug delivery systems to deliver antimicrobials, and vaccination against
common pathogens, reducing the need to use antimicrobials in the first place. For this,
bacteria extracellular vesicles offer a unique solution due to their advantageous
properties of being immunogenic, involved in inter-bacterial communication, and
posing the ability to carry a wide range of therapeutic cargo. However, the process of
isolating natural bacteria extracellular vesicles is often time consuming and produces a
low yield. Hence, this project aims to explore the potential of mimetic bacteria
extracellular vesicles produced via a mechanical shearing method. In this project, we
successfully optimised the method to produce mimetic vesicles from Streptococcus
Pneumonia and Staphylococcus Aureus, resulting in high protein and particle yields as
as compared to natural extracellular vesicles isolated from the same bacteria. While
these vesicles displayed no innate antibacterial activity against Streptococcus
Pneumonia, Staphylococcus Aureus and Klebsiella Pneumonia, significant uptake of
both mimetic and natural vesicles were observed in gram-positive Streptococcus
Pneumonia and Staphylococcus Aureus bacteria. This highlights their potential for use
as antimicrobial drug delivery systems. Furthermore, MTT assay with RAW264.7
macrophage cells showed that mimetic vesicles displayed lower cytotoxicity as
compared to natural vesicles, demonstrating the advantage of using mimetic vesicles.
Results from RT-qPCR experiments also showed that mimetic and natural vesicles
were able to induce similar levels of innate and adaptive immune response. |
|---|